Mouawad Antoine, Boutros Marc, Chartouni Antoine, Attieh Fouad, Kourie Hampig Raphaël
Faculty of Medicine, Université Saint-Joseph de Beyrouth, Beyrouth, Lebanon.
Department of Hematology-Oncology, Université Saint-Joseph de Beyrouth, Beyrouth, Lebanon.
Future Oncol. 2025 Feb;21(4):493-499. doi: 10.1080/14796694.2024.2444862. Epub 2024 Dec 23.
For the past few years, researchers and oncologists have been pushing to find biomarkers that would help predict which treatment option would best work on a patient. Tumor Mutational Burden (TMB) is one of the latest biomarkers that is being studied and considered as a promising agnostic immunotherapy biomarker. However, it still shows controversial results in studies due to the difficulty in finding solid comparable results. This is a consequence of different cutoff definitions among many cancer types, age ranges, and the use of different sequencing assays, in addition to its association with other biomarkers such as PD-L1. Finally, the use of composite biomarkers to assess the genetic signature of a tumor might be the way forward to seriously use TMB as an agnostic biomarker.
在过去几年里，研究人员和肿瘤学家一直在努力寻找生物标志物，以帮助预测哪种治疗方案对患者最有效。肿瘤突变负荷（TMB）是正在研究的最新生物标志物之一，被认为是一种有前景的非特异性免疫治疗生物标志物。然而，由于难以找到可靠的可比结果，它在研究中仍显示出有争议的结果。这是多种癌症类型、年龄范围之间不同的临界值定义，以及使用不同的测序检测方法的结果，此外还因其与其他生物标志物如程序性死亡受体配体1（PD-L1）有关。最后，使用复合生物标志物来评估肿瘤的基因特征可能是将TMB作为一种非特异性生物标志物加以认真应用的前进方向。
